ANUPAM RASAYAN INDIA LTD.
NSE : ANURASBSE : 543275ISIN
CODE : INE930P01018Industry : ChemicalsHouse
: Private
BSE784.25-4.9 (-0.62 % )
PREV CLOSE (Rs.) 789.15
OPEN PRICE (Rs.) 793.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1793
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE784.35 -5.95 (-0.75 % )
PREV CLOSE(Rs.) 790.30
OPEN PRICE (Rs.) 790.30
BID PRICE (QTY) 784.35 (95 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 44058
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 22-Apr-2024 | Anupam Rasayan India informs about newspaper publication | <p style="text-align: justify;">Pursuant to Regulation 47 and Regulation 7 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anupam Rasayan India has informed that it enclosed copies of notice published today on April 22, 2024 in ‘Financial Express' (English language) and ‘Dhabkar' (Gujarati language) newspapers, regarding appointment of Link Intime India, as new Registrar and Share Transfer Agent of the Company. Copies of enclosed newspaper notice shall also be hosted on the Company's website at www.anupamrasayan.com.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 15-Apr-2024 | Anupam Rasayan India informs about disclosure | <p style="text-align: justify;">Anupam Rasayan India has informed that it enclose Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 13, 2024 for Anand Sureshbhai Desai & Shraddha Anand Desai.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 03-Apr-2024 | Anupam Rasayan signs LoI with Prominent Japanese Multinational | <p style="text-align: justify;">Anupam Rasayan has signed Letter of Intent (LoI) worth revenue of $90 million (Rs 743 crore) over next 7 years with one of the leading Japanese company to supply two advance intermediates using fluorination chemistry. These molecules will be manufactured in the company's existing as well as soon to be commercialised fluorination plants.</p><p style="text-align: justify;">Anupam will be the first company in India to manufacture these key molecules within the country, with applications in both the pharmaceutical as well as engineering fluids, the signing of LoI also marks the addition of this new marquee customer.</p><p style="text-align: justify;">Anupam Rasayan India (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India.</p><div style="text-align: justify;"><br></div> |
| 28-Feb-2024 | Announcement Under Regulation 30 - Registration Of A Wholly Owned Subsidiary In USA | We wish to inform you that a wholly owned subsidiary of the Company named "Anupam USA, LLC" has been registered in Delaware, USA. |
| 28-Feb-2024 | Anupam Rasayan India informs about registration of wholly owned subsidiary in USA | <div style="text-align: justify;">Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), Anupam Rasayan India has informed that a wholly owned subsidiary of the Company named ‘Anupam USA, LLC' (WoS) has been registered in Delaware, United States of America. The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A. This intimation will also be available on the website of the Company www.anupamrasayan.com</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 23-Jan-2024 | Anupam Rasayan India informs about allotment of warrants | <p style="text-align: justify;">Anupam Rasayan India has informed that the Board of Directors of Company in its meeting held today January 23, 2024, has approved the allotment of 39,14,886 Warrants convertible into 1 equity share of face value of ?10 each at a price of ? 945.11 per warrant, to the below allottees under non-promoter category on preferential allotment basis: (i) 5,29,038 Warrants to Lata Manek Bhanshali, an individual; (ii) 16,92,924 Warrants to Zeal Global Opportunities Fund, a category-1 foreign portfolio investor; and (iii)16,92,924 Warrants to Zinnia Global Fund PCC - Cell Dewcap, a category-1 foreign portfolio investor. Post the above allotment, the equity share capital of the Company shall stand increased to ?1,13,63,79,000 comprising of 11,36,37,900 Equity Shares of ?10 each, on fully diluted basis (calculated on the basis of equity shares capital as on date, assuming full conversion of Warrants). Post conversion of the Warrants into equal number of Equity Shares of the Company (which shall rank with the then existing fully paid-up Equity Shares), the above mentioned allotees will collectively hold 39,14,886 Equity Shares of the Company. The Board meeting commenced at 9:05 am IST and concluded at 9:20 am IST. This intimation is also being hosted on the Company's website at www.anupamrasayan.com.</p><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 26-Dec-2023 | Anupam Rasayan signs LoI worth $61 million with one of the Leading Japanese MNC Chemical Company | <p style="text-align: justify;">Anupam Rasayan India has signed Letter of Intent (LoI) worth revenue of $61 million (Rs 507 crore) for next 9 years with one of the leading Japanese Chemical company to supply new age polymer intermediate. The supply will commence in CY2024. This product will be manufactured in our existing and new multipurpose manufacturing facilities.</p><p style="text-align: justify;">Anupam Rasayan India (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India.</p><div style="text-align: justify;"><br></div> |
| 26-Dec-2023 | Anupam Rasayan India informs about disclosures | <div style="text-align: justify;">Anupam Rasayan India has informed that it enclosed the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 26-Dec-2023 | Sandhar Technologies, Anupam Rasayan and Infosys to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Sandhar Technologies</span> has executed a sale deed for the purchase of the factory premises on the land admeasuring 34 bigha 06 Bishwa, at Village Mouza Bhatian, Pragna Plassi, Tehsil Nalagarh, Distt, Solan, Himachal Pardesh, for the total consideration of Rs 19 crore. The said purchase is for the consolidation of the existing 2 (two) units of the company (out of which 1 (one) is on the leased premises) and shall be used for the future expansion plan of the Company.</p><p style="text-align: justify;"><span style="font-weight: bold;">Anupam Rasayan</span> has signed Letter of Intent worth revenue of $61 Million ( Rs 507 crore) for next 9 years with one of the leading Japanese Chemical company to supply new age polymer intermediate. The supply will commence in CY2024. This product will be manufactured in its existing and new multipurpose manufacturing facilities.</p><p style="text-align: justify;">The global company has elected to terminate the Memorandum of Understanding with <span style="font-weight: bold;">Infosys</span>, and the parties will not be pursuing the Master Agreement. Infosys was supposed to provide enhanced digital experiences, along with modernisation and business operations services, leveraging Infosys platforms and AI solutions. The total client target spend over 15 years was estimated at $1.5 billion.</p><p style="text-align: justify;">United States Food and Drug Administration (USFDA) has conducted an inspection at <span style="font-weight: bold;">Zydus Lifesciences</span>' API site situated at Changodar, Ahmedabad. This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023. The inspection closed with 6 observations.</p><p style="text-align: justify;"><span style="font-weight: bold;">RITES </span>has signed a memorandum of understanding (MoU) with North Eastern Electric Power Corporation (NEEPCO) to collaborate on consultancy works for strengthening logistical infrastructure at various hydropower stations in the region, including the Siang Basin. To enhance the power infrastructure in the region, the Arunachal Pradesh Government has entrusted NEEPCO for executing five hydropower projects in the Siang Basin. </p><p style="text-align: justify;"><span style="font-weight: bold;">PNC Infratech</span>'s wholly owned subsidiary -- Prayagraj Kaushambi Highway Package 3 has achieved Financial Closure for its Hybrid Annuity Mode (HAM) Project namely Construction of 4-lane highway from Km 49.155 to Km 74.700 (Singraur Uphar to Baranpur Kadipur Ichauli) of NH-73 1A with paved shoulders (including Canga Bridge) in the state of Uttar Pradesh on Hybrid Annuity Mode (Package-III) from the Office of Executive Engineer, National Highways Division, UPPWD, Prayagraj (Project Implementing Authority) December 22, 2023. A bid project cost is Rs 891 crore. Project is to be constructed in 24 months and operated for 15 years, post construction.</p><p style="text-align: justify;"><span style="font-weight: bold;">UPL </span>has received approval for the proposal for fund raising for an amount aggregating upto Rs 4,200 crore subject to receipt of statutory / regulatory approvals, as may be required under applicable law, by way of issue of equity shares on rights issue basis to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with the applicable laws including the Securities and Exchange Board of India (Issue of Capital and Disclosures Requirements) Regulations, 2018 as amended from time to time. The Board of Directors of the Company at its meeting held on December 22, 2023, inter alia, approved the same. </p> |
| 11-Dec-2023 | Anupam Rasayan India informs about press release | <div style="text-align: justify;">Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anupam Rasayan has informed that it enclosed Press Release titled ‘Anupam Rasayan wins CII 3R Award for Best Industry Practices for Managing own Waste' which shall be issued by the Company today i.e. Monday, December 11, 2023. This Press Release will also be available on the website of the Company at www.anupamrasayan.com.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
